- Home
- AUDC vs ANL Comparison
AUDC vs ANL Comparison
Compare AUDC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AUDC | ANL |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 293.4M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AUDC | ANL |
|---|---|---|
| Price | $8.46 | $7.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.50 | ★ $16.00 |
| AVG Volume (30 Days) | 138.6K | ★ 198.6K |
| Earning Date | 05-05-2026 | 04-20-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $0.88 |
| 52 Week High | $11.48 | $12.09 |
Technical Indicators
Market Signals| Indicator | AUDC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 41.84 |
| Support Level | $8.13 | $7.21 |
| Resistance Level | $9.04 | $9.98 |
| Average True Range (ATR) | 0.26 | 0.89 |
| MACD | 0.11 | -0.32 |
| Stochastic Oscillator | 89.19 | 7.95 |
Price Performance
Historical ComparisonAbout AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.